Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children

Pediatric Infectious Disease Journal

Volumn 24, Issue 10, 2005, Pages 874-879

  Ananworanich, Jintanat ^a   Kosalaraksa, Pope ^b   Hill, Andrew ^c   Siangphoe, Umaporn ^a   Bergshoeff, Alina ^d   Pancharoen, Chitsanu ^e   Engchanil, Chulapan ^b   Ruxrungtham, Kiat ^e   Burger, David ^d  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Highly active antiretroviral therapy; Human immunodeficiency virus; Nonnucleoside reverse transcription inhibitors; Nucleoside reverse transcription inhibitors; Protease inhibitors; Resistance; Salvage therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; ATORVASTATIN; CD4 ANTIGEN; CHOLESTEROL; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TRIACYLGLYCEROL; TUBERCULOSTATIC AGENT; VIRUS RNA; ZIDOVUDINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BLOOD SAMPLING; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONVULSION; CORRELATION ANALYSIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; OPEN STUDY; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PHARMACOKINETICS; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; THAILAND; TREATMENT FAILURE; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS GENE; VIRUS LOAD; VOMITING;

EID: 26944437399     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000180578.38584.da     Document Type: Article

References (28)

1. Gortmaker S, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345:1522-1528.
2. Sharland M, Castelli G, Ramos J, Gibb D, on behalf of the PENTA Steering Committee. PENTA guidelines for the use of antiretroviral therapy, 2004. HIV Med. 2004;5(suppl 2):61-86.
3. Nachman S, Stanley K, Yogev R, et al. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomised controlled trial. JAMA. 2000;26:492-498.
4. Kline M, Brundage R, Fletcher C, et al. Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection. Pediatr Infect Dis J. 2001;20:666-671.
5. Grub S, DeLora P, Ludin E, et al. Pharmacokinetics and pharmacodynamics of saquinavir in paediatric patients with human immunodeficiency virus infection. Clin Pharmacol Ther. 2002;71:122-130.
6. Mullen J, Leech S, O'Shea S, et al. Antiretroviral drug resistance among HIV-1 infected children failing treatment J Med Virol. 2002;68: 299-304.
7. Juethner SN, Williamson C, Ristig MB, et al. Nonnucleoside reverse transcriptase inhibitor resistance among antiretroviral-naive HIV-positive pregnant women. J Acquir Immune Defic Syndr. 2003;32:153-156.
8. Fraaij PL, Neubert J, Bergshoeff AS, et al. Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children. Antivir Ther (Engl). 2004;9:297-299.
9. Saez-Llorens X, Vioari A, Deetz C, et al. Forty-eight week evaluation of lopinavir/ritonavir a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2003;22:216-223.
10. Stephan C, Hentig N, Kourbeti I, et al. Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir. AIDS. 2004;18:503-508.
11. Molla A, Mo H, Vasavanonda S, et al. In vitro interaction of lopinavir with other protease inhibitors. Antimicrob Agents Chemother. 2002;46: 2249-2253.
12. Hellinger J, Cohen C, Morris A, et al. A pilot study of saquinavir-SGC (SQV) and lopinavir/ritonavir (LPV/r) twice daily in protease inhibitor (PI)-naive HIV positive individuals: proteae inhibitor concentrations and week 48 results. In: Second IAS Conference on HIV Pathogenesis and Treatment, July 2003, Paris, France. Abstract 571.
13. Staszewski S, Dauer B, Carlebach A, et al. The LOPSAQ study: 12 hour pharmacokinetics analysis of HIV+ patients treated with the salvage regimen lopinavir (LPV/r) plus saquinavir (SQV) without any additional antiretroviral therapy. In: Fifth International Workshop on Clinical Pharmacology of HIV Therapy, April 2004, Rome, Italy. Abstract 6.4.
14. Clotet B, Menedez-Arias L, Schapiro J, et al. Guide to management of HIV Drug Resistance, Antiretroviral Pharmacokinetics and Viral Hepatitis in HIV Infected Subjects. 4th ed. Fundacio de Lluita Contra la SIDA; 2004.
15. Leonard EG, McComsey GA. Metabolic complications of antiretroviral therapy in children. Pediatr Infect Dis J. 2003;22:77-84.
16. Lainka E, Oezbek S, Falck M, et al. Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy. Pediatrics. 2002;110:e56.
17. NCEP Expert Panel on Blood Cholesterol Levels in Children and Adolescents. National Cholesterol Education Program (NCEP) high-lights of the Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics. 1992;89:495-501.
18. McCrindle BW, et al. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr. 2003;142:74-80.
19. Hammer S, Vaida F, Bennett K, et al. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA. 2002;10:169-180.
20. Ebrahim O, Isaacs S, Hill A, et al. Short-course induction with boosted saquinavir monotherapy (SQV/r) for naive patients with late-stage HIV infection in Johannesburg, South Africa. In: Fifteenth International AIDS Conference, July 2004, Bangkok, Thailand. Abstract TuPeB4492.
21. Gathe J, Washington MY, Mayberry C, et al. IMANI-1: single drug HAART: proof of concept study. Pilot study of the safety and efficacy of Kaletra (LPV/r) as single drug HAART in HIV + ARV-naive patients: interim analysis of subjects completing final 48 week data. In: Fifteenth International AIDS Conference, July 2004, Bangkok, Thailand. Abstract MoOrB1057.
22. Autar RS, Ananworanich J, Apateerapong W, et al. Pharmacokinetic (PK) study of saquinavir hard-gel caps/ritonavir (SQV-HGC/RTV) in HIV-1 infected patients: 1600/100 mg OD compared to 2000/100 mg OD and 1000/100 mg BID. Antimicrob Chemother. 2004;54:785-790.
23. Delaguerre C, Teglas J, Treluyer J, et al. Predictive factors for virologic success in HIV-1 infected children treated with lopinavir-ritonavir. J Aqcuir Immune Defic Syndr. 2004;37:1269-1275.
24. Ananworanich J, Hill A, Siangphoe U, et al, for the Staccato Study Group. A prospective study of efficacy and safety of once daily saquinavir/ritonavir plus 2 NRTIs in treatment of naive Thai patients. Antiviral Ther. In press.
25. Yeh V, Barros C, P. Easterbrook P, et al. Virologic response to a once daily lopinavir/ritonavir (LPV/r) based regimen in ARV-naive patients is not associated with trough lopinavir concentrations or baseline HIV RNA and CD4 count. In: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October 30-November 2, 2004. Washington, DC: American Society for Microbiology; 2004. Abstract H-570-363.
26. Delaugerre C, Teglas JP, Treluyer JM, et al. Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2004;37:1269-1275.
27. Hijazi Y, Riek M, Gaudeul-Erhart E, Grange S. Saquinavir 500 mg tablet, a new formulation, has similar bioavailability to Invirase 200 mg capsule for healthy volunteers at 1000/100 mg BID dosing with ritonavir. In: Second IAS Conference on HIV Pathogenesis and Treatment, July 2003, Paris, France. Abstract 53.
28. Ananworanich J, Nuesch R, Le Braz M, et al. Failures of one week on, one week off anti-retroviral therapies. AIDS. 2003;17:F33-F37.